- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04535882
Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
Association Between Serum Leucine-rich Alpha-2 Glycoprotein Levels and Endoscopic Activity of Possible Ulcerative Colitis or Crohn's Disease Colitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy with histology were performed within 7 days.The disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity index (CDAI), respectively. The Mayo endoscopy score was evaluated. UC patients whose Mayo endoscopy score was 2 or 3 were divided into the active UC group.
CD patients whose CDAI >150 were divided into the active CD group.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Masashi Kajiyama, MD
- Phone Number: 3012 81265822121
- Email: kajiyama.masashi@sihp.jp
Study Contact Backup
- Name: Akira Horiuchi, MD
- Phone Number: 3012 81265822121
- Email: horiuchi.akira@sihp.jp
Study Locations
-
-
Nagano
-
Komagane, Nagano, Japan, 399-4117
- Recruiting
- Showa Inan General Hospital
-
Contact:
- Yamaguchi Yukari
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients whom possible UC or Crohn disease was suspected
Exclusion Criteria:
- other autoimmune diseases
- acute or chronic renal failure
- chronic heart diseases
- liver cirrhosis
- cancer
- acute or chronic infections
- ischemic colitis
- infectious colitis
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum LRG measurement
Time Frame: one year
|
Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients.
|
one year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LRG
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on LRG Levels
-
National Cancer Institute (NCI)CompletedHPV16 Anitbody Levels Post Vaccination | HPV18 Antibody Levels Post VaccinationUganda
-
KGK Science Inc.Healthy Directions, LLCCompletedCoQ10 Blood Levels | CoQ10 Blood Levels With Statin UseCanada
-
Democritus University of ThraceActive, not recruitingCholesterol LevelsGreece
-
Parkland Health and Hospital SystemCompletedStress LevelsUnited States
-
Bucci Laser Vision InstituteCompletedCardioprotective LevelsUnited States
-
Chi-Jane WangCompleted
-
Tel-Aviv Sourasky Medical CenterUnknownBlood Antibiotic Levels
-
University of British ColumbiaUniversity of British Columbia School of Population and Public HealthCompleted
-
Children's Hospital of PhiladelphiaChildren's Anesthesiology Associates, Ltd.Completed
-
Colgate PalmoliveCompleted